Trial Profile
An Open-Label, Multi-Center, Follow up Study to Protocol 101/2 - Continued Treatment by Intravenously Administered IPL344 to Amyotrophic Lateral Sclerosis (ALS) Patients
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs IPL-344 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Immunity Pharma
- 03 Dec 2023 Planned End Date changed from 1 Dec 2022 to 1 Feb 2026.
- 03 Dec 2023 Planned primary completion date changed from 1 Nov 2022 to 1 Jan 2026.
- 03 Dec 2023 Status changed from recruiting to suspended due to IPL344 shortage and may resume once drug supply is available. Survival follow-up is being done following participants' consent.